Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 42

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 42
---
 allow third parties to commercialize our technology and compete
directly with us, without payment to us.

The issuance of a patent is
not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices
in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed,
invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar
or identical products and techniques, or limit the duration of the patent protection of our technology.

<div align='center'>29</div>

While we are aware of several
third-party patents of interest, we do not believe that any of our products infringe any valid claims of patents or other proprietary
rights held by others. However, there can be no assurances that we do not infringe any patents or other proprietary rights held by
third parties. If our products were found to infringe any proprietary right of another party, we could be required to pay significant
damages or license fees to such party and/or cease production, marketing and distribution of those products. Litigation may also be necessary
to defend infringement claims of third parties or to enforce patent rights we hold or to protect trade secrets or techniques we own.

We also rely on trade secrets
and other unpatented proprietary technology. There can be no assurances that we can meaningfully protect our rights in our unpatented
proprietary technology or that others will not independently develop substantially equivalent proprietary products or processes or otherwise
gain access to our proprietary technology. We seek to protect our trade secrets and proprietary know-how, in part, with confidentiality
agreements with employees and consultants that include customary intellectual property assignment obligations. There can be no assurances,
however, that the agreements will not be breached, adequate remedies for any breach would be available or competitors will not discover
our trade secrets or independently develop comparable intellectual property.

Obtaining and maintaining patent protection depends on compliance with various procedures, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

The USPTO, and various foreign
governmental patent agencies require compliance with a number of procedures, documentary, fee payment and other similar provisions during
the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on
issued patents